Latest Clinical Trials News

Vectus Biosystems has temporarily paused trading of its securities pending a forthcoming announcement, signaling potential material news for investors.

Biotron Limited is set to acquire Sedarex Limited, gaining global patents for SedRx, a next-generation general anaesthetic, supported by a $2.5 million capital raising to fund regulatory and development milestones.

Compumedics has secured a $2.15 million placement to fast-track commercialisation of its Somfit D device following early FDA approval, positioning the company for significant growth in the US home sleep testing market.

Actinogen Medical has secured an initial $5.5 million R&D tax incentive rebate from the Australian Tax Office, with an additional $1.9 million pending, bolstering funding for its Alzheimer’s and depression drug trials.

Argenica Therapeutics reports encouraging functional improvements in stroke patients treated with ARG-007, setting the stage for a targeted Phase 2b trial focused on patient-centered outcomes.

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.

Clarity Pharmaceuticals’ Co-PSMA Phase II trial shows its Cu-SAR-bisPSMA diagnostic agent detects more prostate cancer lesions than current standard imaging, promising earlier and more accurate recurrence detection.

Tryptamine Therapeutics has enrolled the first patient in its pioneering clinical trial testing TRP-8803, an IV-infused psilocin formulation, for Binge Eating Disorder. The study aims to evaluate safety and efficacy, potentially reshaping treatment options for millions.

EMVision Medical Devices has received a $3 million government grant to fund a clinical study demonstrating its emu™ brain scanner's impact on accelerating stroke diagnosis in rural emergency departments.

Resonance Health reveals a robust growth strategy targeting $17 million revenue by FY26, powered by AI-enhanced medical imaging and global clinical trial services expansion.

Cryosite Limited reports a strong start to FY26 with a 22% revenue increase and a strategic warehouse acquisition that doubles capacity, positioning the company for sustained growth in clinical trial logistics.

INOVIQ Limited has launched an A$11.5 million capital raise to fast-track clinical validation and commercialization of its ovarian cancer screening test and advance its CAR-exosome therapeutic program targeting solid tumors.